SCHEMBL2326970

SCHEMBL2326970

O=C(O)C1C2CCC(O2)C1C(=O)N1CCN(Cc2ccccc2)CC1

nearest known ligand 0.68

Predicted protein targets (top 10)

geneUniProtsupporting neighboursconfidence
TFPI2 P48307 8/20 0.68
PPP5C P53041 2/20 0.57
PPP2CA P67775 1/20 0.57
NPY4R P50391 1/20 0.57
ALDH1A1 P00352 2/20 0.54
MEN1 O00255 1/20 0.53
TSHR P16473 1/20 0.53
KMT2A Q03164 1/20 0.53
POLB P06746 1/20 0.51
CYP2C19 P33261 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19341777 1.00 TFPI2 (0.68) TFPI2PPP5CPPP2CANPY4RALDH1A1
SCHEMBL9880151 1.00 TFPI2 (0.68) TFPI2PPP5CPPP2CANPY4RALDH1A1
SCHEMBL13556913 0.88 ALDH1A1 (0.53) TFPI2ALDH1A1MEN1TSHRKMT2A
SCHEMBL2331589 0.87 TFPI2 (0.52) TFPI2ALDH1A1MEN1TSHRKMT2A
SCHEMBL12443568 0.85 TFPI2 (0.50) TFPI2ALDH1A1MEN1TSHRKMT2A
SCHEMBL9880152 0.82 ALDH1A1 (0.54) ALDH1A1MEN1TSHRKMT2APOLB
SCHEMBL31195314 0.81 TFPI2 (1.00) TFPI2PPP5CPPP2CANPY4RTSHR
SCHEMBL1219408 0.80 CYP2C19 (0.67) TFPI2PPP5CPPP2CANPY4RALDH1A1
SCHEMBL1219410 0.80 CYP2C19 (0.67) TFPI2PPP5CPPP2CANPY4RALDH1A1
SCHEMBL3495133 0.79 SMN1; SMN2 (0.68) TFPI2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10399993-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2019-09-03 US disclosed
US-10399993-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2019-09-03 US disclosed
US-20180370983-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. (US) 2018-12-27 US disclosed
US-10023587-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2018-07-17 US disclosed
US-10023587-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2018-07-17 US disclosed
US-10023587-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2018-07-17 US disclosed
US-20170369503-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. (US) 2017-12-28 US disclosed
US-20170369503-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. (US) 2017-12-28 US disclosed
EP-2124550-B1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY INC (US) 2017-04-19 EP disclosed
EP-2124550-B1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY INC (US) 2017-04-19 EP disclosed
US-8426444-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2013-04-23 US disclosed
US-20120270736-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. (US) 2012-10-25 US disclosed
US-20120270736-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHNOLOGY, INC. (US) 2012-10-25 US disclosed
US-7998957-B2 Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2011-08-16 US disclosed
US-7998957-B2 Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. (US) 2011-08-16 US disclosed
EP-2124550-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE Lixte Biotechnology Holdings, Inc. (US) 2009-12-02 EP disclosed
US-20090036309-A1 Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. 2009-02-05 US disclosed
US-20090036309-A1 Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use LIXTE BIOTECHNOLOGY, INC. 2009-02-05 US disclosed
WO-2008097561-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHOLOGY HOLDINGS, INC. (US) 2008-08-14 WO disclosed
WO-2008097561-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE LIXTE BIOTECHOLOGY HOLDINGS, INC. (US) 2008-08-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120270736-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE HCCS, OXA1L, OTC TFPI2 4858/4885PPP5C 3037/4885PPP2CA 2107/4885
US-20090036309-A1 Oxabicycloheptanes and oxabicylcoheptenes, their preparation and use HCCS, VHL, OXA1L TFPI2 4843/4885PPP5C 2860/4885PPP2CA 2048/4885
US-10399993-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use HCCS, OXA1L, OTC TFPI2 4858/4885PPP5C 3037/4885PPP2CA 2107/4885
US-20180370983-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE HCCS, OXA1L, OTC TFPI2 4858/4885PPP5C 3037/4885PPP2CA 2107/4885
US-20170369503-A1 OXABICYCLOHEPTANES AND OXABICYCLOHEPTENES, THEIR PREPARATION AND USE HCCS, OXA1L, OTC TFPI2 4858/4885PPP5C 3037/4885PPP2CA 2107/4885
US-10023587-B2 Oxabicycloheptanes and oxabicycloheptenes, their preparation and use HCCS, OXA1L, OTC TFPI2 4858/4885PPP5C 3037/4885PPP2CA 2107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.